Title of article :
Low Prevalence of Occult Hepatitis B Infection Among Blood Donors in Beirut,
Lebanon: Reconsider the Deferral Strategy of Anti-HBc Positive Blood
Donors
Author/Authors :
El Banna Nour نويسنده Faculty of Health Sciences, University of Balamand,
Beirut, Lebanon , El Jisr Tamima نويسنده Laboratory Medicine, Makassed General Hospital, Beirut,
Lebanon , Samaha Hanadi نويسنده Laboratory Medicine, Saint Georges University Medical
Centre, Beirut, Lebanon , El Chaar Mira نويسنده Faculty of Health Sciences, University of Balamand,
Beirut, Lebanon
Abstract :
Background Hepatitis B virus (HBV) infection remains one of the
major infectious threats to human health. Since the implementation of
highly sensitive HBV nucleic acid testing, occult HBV infection (OBI)
has been detected. Occult HBV infection is characterized by a positive
HBV DNA test with undetectable HBsAg (Hepatits B surface antigen). The
prevalence of OBI varies significantly between geographic areas,
genotypes, and population depending on the sensitivity of the detection
assays used. Objectives This project aimed at determining the prevalence
of OBI in blood donors from a major blood donor center in Beirut,
Lebanon through testing for 4 HBV markers (HBsAg, anti-HBs, anti-HBc and
HBV DNA). Methods A total of 7437 blood donors were first tested for
anti-HBc marker between August 2013 and March 2015; samples positive for
anti-HBc were tested for other serological markers and HBV genome. DNA
was extracted from 500 μL of plasma and tested for HBV DNA using Artus
HBV TM PCR Kit assay. All anti-HBc positive samples were tested by
nested PCR, targeting the S gene. Results This study revealed a 4.6%
prevalence of anti-HBc positive blood donors (341/7437). Among anti-HBc
positive blood donors, 21 were HBsAg positive (6.2%) and 75% were
positive for anti-HBs. The occurrence of occult hepatitis B virus in
healthy seropositive blood donors during a 20 month period was very low;
only 1 Syrian blood donor (n = 1/341, 0.3%) was HBsAg negative, HBV
DNA-positive with anti-HBs level > 1000 mIU/mL. Conclusions Our
study indicates that HBV DNA is present in a small percentage of HBsAg
negative, anti-HBc reactive units. Lebanon has developed its own blood
screening strategy, which is to screen for anti-HBc in addition to
HBsAg. This is based on HBV prevalence and cost-effectiveness of testing
methods. The disadvantage of not implementing nucleic acid testing (NAT)
is missing rare blood units from donors in the window period.
Journal title :
Astroparticle Physics